Top Markets
#1 Helium Helium +110.72%
#2 MowCat MowCat +83.79%
#3 Seeker Seeker +72.11%
#4 AI XOVIA AI XOVIA +52.42%
#5 UnifAI Network UnifAI Network +33.65%
#6 Pons Pons +30.52%
#7 Tensor Tensor +26.60%
#8 TENDIES TENDIES +25.33%
#9 pipedog pipedog +22.04%
#10 Zylo Ecosystem Zylo Ecosystem +21.96%
Coin of the day
Helium Helium
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Classifica tra le azioni #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Prezzo delle azioni
$8.74
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$699.74M
Variazione (1 giorno)
-4.85%
Variazione (1 anno)
-2.29%
Paese
US
Scambia BridgeBio Oncology Therapeutics Inc. (BBOT)

Categoria

Healthcare
Utile per BridgeBio Oncology Therapeutics Inc. (BBOT)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di BridgeBio Oncology Therapeutics Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di BridgeBio Oncology Therapeutics Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH